Taiwan

Acepodia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors

Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate

Therapeutic Area: Oncology Product Name: ACE1702

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2020

Details:

The study will evaluate the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing solid tumors not amenable to surgery or other therapeutic options.

Acepodia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II

Lead Product(s): ACE1702

Therapeutic Area: Oncology Product Name: ACE1702

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

The data was presented in a digital poster session at the 2020 AACR Annual Meeting II. ACE1702 is Acepodia’s lead off-the-shelf cell therapy candidate and recently received investigational new drug clearance from the U.S. FDA to be evaluated in Phase 1 clinical trials.

Acepodia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020

Lead Product(s): ACE1702

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 08, 2020

Details:

Preclinical data for early stage ACC- and CAR-oNK cell therapy candidates demonstrate promise in models of solid tumors and hematological malignancies .

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Acepodia

Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors

Acepodia

Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II

Acepodia

Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020